Our study establishes IGFBP6 as a therapeutic target in sepsis through 4 key findings: (a) Elevated circulating IGFBP6 levels in adult and pediatric patients with sepsis correlate with disease severity compared with healthy and non-septic infection controls. This evidence concerns the gene IGFBP6 and infection.